Novo Nordisk(US:NVO) GLP1减重宝典·2025-05-08 04:16Core Viewpoint - Novo Nordisk has announced the cessation of the weekly oral semaglutide tablet development due to strategic portfolio decisions, while continuing to advance other oral semaglutide delivery options targeting metabolic diseases and obesity [1][4]. Group 1: Financial Performance - Novo Nordisk reported its financial performance for Q1 2025, highlighting the strategic decision to stop the development of the weekly oral semaglutide tablet [1]. Group 2: Regulatory Developments - Earlier this year, multiple media outlets reported that Novo Nordisk submitted a new application to the FDA for a 25 mg oral semaglutide for the treatment of overweight and obesity, making it the first oral GLP-1 therapy seeking regulatory approval specifically for weight loss [3]. Group 3: Clinical Trial Results - In early clinical trials of the daily oral semaglutide, participants with an average starting weight of 105.4 kg experienced a 17.4% average weight loss after 68 weeks on a 50 mg daily regimen, compared to only 1.8% in the placebo group, with 89.2% of the treatment group losing at least 5% of their body weight versus 24.5% in the placebo group [3].